Evidence map›Paper›PMID 18157593›Full record

ReviewWiener medizinische Wochenschrift (1946)2007

[Biomarkers - the way towards individualized chemotherapy in non-small cell lung cancer (NSCLC)].

Sabine Danzinger, Martin Filipits

Abstract readReview
PubMed Publisher
In one paragraph

Review in Wiener medizinische Wochenschrift (1946), 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Sabine DanzingerInstitut für Krebsforschung, Universitätsklinik für Innere Medizin I, Medizinische Universität Wien, Wien, Osterreich.
Martin Filipits
Medical University of Vienna · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor biology is increasingly important when choosing the optimal therapy for patients with non-small cell lung cancer (NSCLC). A number of potential biomarkers is under investigation in the hope that it will be possible to identify markers that assist in the selection of patients for specific therapies in the future. Patients with an elevated DNA repair capacity, indicated by an increased tumoral expression of excision repair cross complementation group-1 (ERCC1) or ribonucleotid reductase subunit M1 (RRM1) may benefit less from cisplatin-based and gemcitabine-based chemotherapy, respectively. Overexpression of the cell cycle regulator p27 affects response to various anticancer drugs and increased levels of class III beta-Tubulin are associated with taxane resistance. Promising results so far suggest that customized therapy for individual patients with the help of predictive biomarkers is possible and it is likely that this strategy will improve treatment of NSCLC in the future.

Indexed as

Antineoplastic AgentsBiomarkers, TumorCarcinoma, Non-Small-Cell LungCyclin-Dependent Kinase Inhibitor p27DNA-Binding ProteinsEndonucleasesGene Expression Regulation, NeoplasticHumansLung NeoplasmsPrognosisProspective StudiesRandomized Controlled Trials as TopicRibonucleoside Diphosphate ReductaseTubulinTumor Suppressor ProteinsAntineoplastic AgentsBiomarkers, TumorCyclin-Dependent Kinase Inhibitor p27DNA-Binding ProteinsEndonucleasesERCC1 protein, humanRibonucleoside Diphosphate ReductaseRRM1 protein, humanTUBB3 protein, humanTubulinTumor Suppressor Proteins

Identifiers

PMID18157593
OpenAlexW68842744

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.